Automate Your Wheel Strategy on DXCM
With Tiblio's Option Bot, you can configure your own wheel strategy including DXCM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DXCM
- Rev/Share 12.0559
- Book/Share 7.1011
- PB 10.3167
- Debt/Equity 0.5061
- CurrentRatio 1.8825
- ROIC 0.1661
- MktCap 28572591647.0
- FreeCF/Share 2.7856
- PFCF 26.5249
- PE 33.875
- Debt/Assets 0.2192
- DivYield 0
- ROE 0.3244
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 3
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | DXCM | Barclays | Equal Weight | Underweight | -- | $71 | Jan. 12, 2026 |
| Upgrade | DXCM | Morgan Stanley | Equal Weight | Overweight | -- | $75 | Dec. 2, 2025 |
| Initiation | DXCM | Evercore ISI | -- | In-line | -- | $68 | Nov. 25, 2025 |
| Resumed | DXCM | Stifel | -- | Buy | -- | $85 | Oct. 21, 2025 |
| Downgrade | DXCM | Oppenheimer | Outperform | Perform | -- | -- | Sept. 8, 2025 |
| Initiation | DXCM | Argus | -- | Buy | -- | $100 | Aug. 21, 2025 |
| Initiation | DXCM | Truist | -- | Buy | -- | $102 | June 16, 2025 |
| Initiation | DXCM | Goldman | -- | Buy | -- | $104 | May 30, 2025 |
| Initiation | DXCM | Mizuho | -- | Outperform | -- | $85 | April 10, 2025 |
| Upgrade | DXCM | Redburn Atlantic | Neutral | Buy | $85 | $115 | Feb. 3, 2025 |
News
Got $10,000? I Think DexCom Stock Could Be a Quiet Winner of the GLP‑1 Wars
Published: February 25, 2026 by: The Motley Fool
Sentiment: Neutral
Analysts feared the advent of GLP-1 medications would harm DexCom's blood glucose monitoring devices. However, as its turns out, DexCom's devices are being prescribed together with GLP-1s.
Read More
Got $10,000? I Think DexCom Stock Could Be a Quiet Winner of the GLP‑1 Wars
Published: February 25, 2026 by: The Motley Fool
Sentiment: Neutral
Analysts feared the advent of GLP-1 medications would harm DexCom's blood glucose monitoring devices. However, as its turns out, DexCom's devices are being prescribed together with GLP-1s.
Read More
Why DexCom (DXCM) is a Top Growth Stock for the Long-Term
Published: February 20, 2026 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
The Big 3: VZ, DXCM, AMAT
Published: February 19, 2026 by: Schwab Network
Sentiment: Positive
Dan Deming sees the rotation trade continuing if markets can hold recent momentum this trading week. As for the Big 3, he sees a breakout candidate in Verizon (VZ), DexCom's (DXCM) potential to continue its recent upside momentum, and Applied Materials (AMAT) serving as a rising giant in the semiconductor trade.
Read More
DexCom Stock Falls Despite Q4 Earnings Beat, G7 Rollout Drives Growth
Published: February 13, 2026 by: Zacks Investment Research
Sentiment: Positive
DXCM beats Q4 EPS estimates, posts 13% revenue growth and reiterates 2026 guidance as G7 15 Day rollout and margin gains drive momentum.
Read More
Will DXCM Deliver Q4 Earnings Beat on G7 Stabilization, Volume Growth?
Published: February 10, 2026 by: Zacks Investment Research
Sentiment: Positive
DexCom heads into Q4 earnings with easing G7 issues, improving supply chains and rebounding U.S. new customer starts lifting revenue outlook.
Read More
Countdown to DexCom (DXCM) Q4 Earnings: Wall Street Forecasts for Key Metrics
Published: February 10, 2026 by: Zacks Investment Research
Sentiment: Neutral
Evaluate the expected performance of DexCom (DXCM) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Read More
DXCM Upgrades Stelo With AI-Powered Smart Meal Logging Features
Published: February 05, 2026 by: Zacks Investment Research
Sentiment: Positive
Dexcom plans a nationwide AI upgrade to Stelo, adding a million-plus food database and smarter insights to improve glucose understanding and wellness goals.
Read More
DexCom (DXCM) Reports Next Week: Wall Street Expects Earnings Growth
Published: February 05, 2026 by: Zacks Investment Research
Sentiment: Positive
DexCom (DXCM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
DexCom (DXCM) is a Top-Ranked Growth Stock: Should You Buy?
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Positive
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Read More
Here's Why DexCom (DXCM) is a Strong Momentum Stock
Published: January 28, 2026 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
DexCom Stock Declines Following Strong Preliminary Q4 Results
Published: January 16, 2026 by: Zacks Investment Research
Sentiment: Negative
DXCM posts strong preliminary Q4 and full-year 2025 revenue growth, beating estimates, though shares slip after the announcement.
Read More
Here's Why You Should Hold DexCom Stock in Your Portfolio for Now
Published: January 16, 2026 by: Zacks Investment Research
Sentiment: Positive
DXCM looks poised for growth as CGM demand expands, G7 and One+ adoption accelerates, and strong Q4 results support a hold stance.
Read More
Halper Sadeh LLC Encourages DexCom, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Published: January 15, 2026 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of DexCom, Inc. (NASDAQ: DXCM) breached their fiduciary duties to shareholders. If you currently own DexCom stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal righ.
Read More
DexCom, Inc. (DXCM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Published: January 13, 2026 by: Seeking Alpha
Sentiment: Neutral
DexCom, Inc. (DXCM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Read More
3 Stocks Likely to Gain From Rising HSA Contribution & Medicare Premium
Published: December 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Rising HSA limits and higher Medicare premiums in 2026 could lift demand for chronic care devices from DexCom, ResMed and Masimo.
Read More
DXCM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that DexCom, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: December 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against DexCom, Inc. (“DexCom” or “the Company”) (NASDAQ: DXCM) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired DexCom securities between January 8, 2024 and September 17, 2025, both dates inclusive (the “Class Period”).
Read More
DexCom, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before December 26, 2025 to Discuss Your Rights - DXCM
Published: December 26, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Dec. 26, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of DexCom investors who were adversely affected by alleged securities fraud between January 8, 2024 and September 17, 2025.
Read More
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: December 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Dec. 26, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DexCom, Inc. (“DexCom” or “the Company”) (NASDAQ: DXCM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 26, 2024 and September 17, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before December 26, 2025.
Read More
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of DexCom, Inc.(DXCM) Shareholders
Published: December 23, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Dec. 23, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of DexCom investors who were adversely affected by alleged securities fraud between January 8, 2024 and September 17, 2025.
Read More
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 26, 2025 in DexCom, Inc. Lawsuit – DXCM
Published: December 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Dec. 22, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM).
Read More
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against DexCom, Inc. (NASDAQ: DXCM)
Published: December 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) between January 8 , 202 4 and September 17 , 202 5, inclusive.. Should You Join This Class Action Lawsuit?
Read More
DexCom, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - DXCM
Published: December 22, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Dec. 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM). Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
Investors who lost money on DexCom, Inc. (DXCM) should contact Levi & Korsinsky about pending Class Action - DXCM
Published: December 19, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Dec. 19, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of DexCom investors who were adversely affected by alleged securities fraud between January 8, 2024 and September 17, 2025.
Read More
Halper Sadeh LLC Encourages DexCom, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Published: December 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
Shareholders should contact the firm immediately as there may be limited time to enforce your rights Shareholders should contact the firm immediately as there may be limited time to enforce your rights
Read More
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: December 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Dec. 18, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DexCom, Inc. (“DexCom” or “the Company”) (NASDAQ: DXCM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 26, 2024 and September 17, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before December 26, 2025.
Read More
DexCom, Inc. Class Action: The Gross Law Firm Reminds DexCom Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 26, 2025 - DXCM
Published: December 18, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Dec. 18, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM). Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
Here's Why You Should Hold DexCom Stock in Your Portfolio for Now
Published: December 17, 2025 by: Zacks Investment Research
Sentiment: Positive
DXCM's strong Q3 growth, expanding CGM coverage and innovation-driven momentum position it for sustained adoption despite rising competition.
Read More
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against DexCom, Inc. (NASDAQ: DXCM)
Published: December 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) between January 8 , 202 4 and September 17 , 202 5, inclusive.. Should You Join This Class Action Lawsuit?
Read More
About DexCom, Inc. (DXCM)
- IPO Date 2005-04-14
- Website https://www.dexcom.com
- Industry Medical - Devices
- CEO Jacob Steven Leach
- Employees 10200